Vanda Pharmaceuticals Inc. (VNDA)

14.61
0.05 0.34
NASDAQ : Health Technology
Prev Close 14.66
Open 14.66
Day Low/High 14.35 / 14.77
52 Wk Low/High 13.33 / 33.44
Volume 457.89K
Avg Volume 684.00K
Exchange NASDAQ
Shares Outstanding 52.96M
Market Cap 789.16M
EPS 0.50
P/E Ratio 35.61
Div & Yield N.A. (N.A)
5 Stocks Ready to Break Out

5 Stocks Ready to Break Out

These stocks look poised to break out and trade higher from current levels.

Vanda, FDA and $500K Bonus Paid to a Mystery Regulatory Consultant

Vanda, FDA and $500K Bonus Paid to a Mystery Regulatory Consultant

Why is Vanda spending a huge amount of money in cash bonuses to a consultant working to get its sleep disorder drug approved?

Short Interest Expands By 40.3% For VNDA

Short Interest Expands By 40.3% For VNDA

The most recent short interest data has been released by the NASDAQ for the 07/15/2013 settlement date, which shows a 1,018,126 share increase in total short interest for Vanda Pharmaceuticals Inc , to 3,547,106, an increase of 40.26% since 06/28/2013. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech Stock Mailbag: GTx, Vanda, Pharmacyclics

Biotech columnist Adam Feuerstein answers readers' questions about health care companies.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look ready to break out and trade higher from current levels.

Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.

Law Offices Of Todd M. Garber Announces Investigation Of Vanda Pharmaceuticals, Inc.

The Law Offices of Todd M. Garber announces that it is investigating potential claims against Vanda Pharmaceuticals, Inc.

Vanda Pharmaceuticals Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Vanda Pharmaceuticals Shareholder Alert: Briscoe Law And Powers Taylor Investigate Possible Breaches Of Fiduciary Duty By Officers And Directors

Former United States Securities and Exchange Commission attorney Willie Briscoe, founder of The Briscoe Law Firm, PLLC, and the securities litigation firm of Powers Taylor, LLP announce that a federal class action...

Best And Worst Performing Biotech Stocks In the Second Quarter

Best And Worst Performing Biotech Stocks In the Second Quarter

Clovis Oncology and Stemline Therapeutics were among the best-performing biotech stocks in the June quarter.

Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

Washington, DC Law Firm Finkelstein Thompson LLP Investigates Vanda Pharmaceuticals, Inc.

Shareholder law firm Finkelstein Thompson LLP is investigating potential claims on behalf of shareholders of Vanda Pharmaceuticals, Inc.

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

Biotech Stock Mailbag: PTC Therapeutics, Vanda, MannKind

Biotech columnist Adam Feuerstein answers readers' questions about healthcare companies.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Vanda Pharmaceuticals, Inc.

SHAREHOLDER ALERT: The Law Firm Of Levi & Korsinsky, LLP Launches An Investigation Into Possible Breaches Of Fiduciary Duty By Vanda Pharmaceuticals, Inc.

Levi & Korsinsky is investigating potential claims on behalf of purchasers of Vanda Pharmaceuticals, Inc.

Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Vanda Pharmaceuticals, Inc.

Law Firm Of Wohl & Fruchter LLP Announces Investigation Of Vanda Pharmaceuticals, Inc.

The law firm of Wohl & Fruchter LLP announces that it is investigating possible violations of federal securities laws by officers and directors of Vanda Pharmaceuticals, Inc.

Stock Futures Waver as Investors Go On Bernanke-Watch

Stock Futures Waver as Investors Go On Bernanke-Watch

Stock futures are wavering Wednesday as investors eagerly await the conclusion of the two-day Federal Reserve meeting.

Vanda's Sleep Disorder Drug Is A Nightmare

Vanda's Sleep Disorder Drug Is A Nightmare

FDA approval of tasimelteon is unlikely because Vanda changed the study design and mis-enrolled patients.

Raise Cash Ahead of Fed News

The market could take off on a bullish surprise, but binary events are always tough to trade.

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Commit To Purchase Vanda Pharmaceuticals At $7, Earn 21.1% Annualized

Investors eyeing a purchase of Vanda Pharmaceuticals Inc shares, but cautious about paying the going market price of $9.27/share, might benefit from considering selling puts among the alternative strategies at their disposal. One interesting put contract in particular, is the December put at the $7 strike, which has a bid at the time of this writing of 80 cents.

Biotech Stock Mailbag: Amarin

Biotech Stock Mailbag: Amarin

Biotech columnist Adam Feuerstein answers readers' questions about health-care companies.

Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA)

Vanda Pharmaceuticals Inc. Stock Downgraded (VNDA)

Vanda Pharmaceuticals (Nasdaq:VNDA) has been downgraded by TheStreet Ratings from from a hold to sell.

Biotech Stock Mailbag: Exelixis

Biotech Stock Mailbag: Exelixis

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

5 Stocks Setting Up to Break Out

5 Stocks Setting Up to Break Out

These stocks look poised to break out and trade significantly higher from current levels.

Biotech Stock Mailbag: Bio-Hazards

Biotech Stock Mailbag: Bio-Hazards

Biotech columnist Adam Feuerstein answers readers' questions and concerns about health care and drug-related stocks.

Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA)

Vanda Pharmaceuticals Inc. Stock Upgraded By TheStreet Ratings (VNDA)

Vanda Pharmaceuticals (Nasdaq:VNDA) has been upgraded by TheStreet Ratings from a sell to hold.

Vanda's Fanapt Falls Flat

Vanda's Fanapt Falls Flat

Vanda's schizophrenia drug closes 2010 with just $31 million in sales, far below expectations.

Clinical Data: Bulls and Bears Round Two

Clinical Data: Bulls and Bears Round Two

Clinical Data's new antidepressant is approved but bulls want the company to be sold for an even higher premium while bears say any deal is unlikely.

10 Unloved Stocks to Rise Up to 120%

10 Unloved Stocks to Rise Up to 120%

These five-star stocks trade at huge discounts to fair value and could soar in 2011.

Biotech Stock Mailbag - Titan Pharma

Biotech Stock Mailbag - Titan Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Exact Sciences

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag: Avanir Pharma

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

Biotech Stock Mailbag - 2Q Updates

Biotech columnist Adam Feuerstein answers readers' questions about drug and health care-related firms.

TheStreet Quant Rating: C (Hold)